1 / 2

Medtech startup Axio Biosolutions secures $7.4m funding from Ratan Tata

Read more about Medtech startup Axio Biosolutions secures $7.4m funding from Ratan Tata on Business Standard. MedTech is the first Indian company to launch an emergency haemostat for trauma care

priya32438
Télécharger la présentation

Medtech startup Axio Biosolutions secures $7.4m funding from Ratan Tata

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medtech startup Axio Biosolutions secures $7.4m funding from Ratan Tata Medtech startup Axio Biosolutions raised $7.4 million funding in Series B round from Ratan Tata's RNT Capital, which will be used for expansion to new markets, and development of high-impact medical products. The first Indian company to launch an emergency haemostat for trauma care, Axio Biosolutions' flagship invention, Axiostat, is a patented and CE-approved product that has prevented countless deaths due to haemorrhage and grievous injuries. The first-aid dressing stops uncontrollable bleeding within just 2-3 minutes of its application, thus saving lives. Axiostat is the de-facto product of Indian armed forces after being used in the surgical strike to save the lives of soldiers and is now an essential part of their field kit. The product caters to the Indian Armed

  2. Forces, BSF, NSG, para-military forces, hospitals and emergency services in India and across the globe. "Uncontrolled bleeding is one of the leading causes of death from traumatic injuries. We are grateful to make a meaningful impact in this space by saving lives of innocent victims. The current round of funding will help us expand into new markets and introduce more products in the wound care and drug delivery space", said Leo Mavely, Founder and CEO of Axio Biosolutions. Headquartered in Boston, Axio Biosolutions has its corporate office in Bengaluru and GMP-certified manufacturing facility in Gujarat. The company has built a strong R&D structure, with multiple patents to its credit in the wound healing, mucoadhesive drug delivery, and hemostats space. Apart from the Tata emeritus, existing investors Accel Partners and IDG Ventures India also participated in this round of funding. Article By - Business Standard

More Related